Hagens Berman Sobol Shapiro LLP announced a securities class action against PROCEPT BioRobotics Corporation, alleging the company used undisclosed late-quarter bulk discounts to pull forward sales of its single-use handpieces and inflate reported revenue. The lawsuit covers investors who purchased or otherwise acquired PROCEPT common stock from February 28, 2024, through February 25, 2026. The complaint focuses on disclosures about handpiece sales tied to PROCEPT's Aquablation therapy for enlarged-prostate patients. The firm alleges that handpiece sales exceeded procedures in every quarter since the first quarter of 2023, leaving more than 10,000 units of cumulative excess customer inventory. PROCEPT's shares had fallen $22.06, or more than 48%, from their August 6, 2025, close by February 25, 2026, after disclosures including weaker-than-expected sales, reduced guidance and elimination of the bulk-discount program. Investors with substantial losses have until September 22, 2026, to seek appointment as lead plaintiff or contact the firm regarding the investigation.